Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nibrozetone - EpicentRx

Drug Profile

Nibrozetone - EpicentRx

Alternative Names: RRx-001

Latest Information Update: 16 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RadioRx
  • Developer EpicentRx; SciClone Pharmaceuticals; The University of Queensland
  • Class Anti-inflammatories; Antianaemics; Antidementias; Antifibrotics; Antineoplastics; Antiparkinsonians; Azetidines; Cytoprotectives; Nitro compounds; Radiosensitisers; Small molecules
  • Mechanism of Action CD47 antigen inhibitors; Free radical stimulants; Inflammasome inhibitors; Macrophage stimulants; NLRP3 protein inhibitors; Proto oncogene protein c-myc inhibitors; SIRPA protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Neuroendocrine tumours; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Small cell lung cancer
  • Phase II Cholangiocarcinoma; Colorectal cancer; Mucositis; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer
  • Phase I CNS cancer; Solid tumours
  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Endometriosis; Myocardial infarction; Parkinson's disease; Pulmonary fibrosis
  • No development reported Brain metastases; Glioblastoma; Glioma; Lymphoma; Multiple myeloma; Sickle cell anaemia

Most Recent Events

  • 02 Apr 2024 EpicentRx initiates a phase II KEVLARx trial in Mucositis in USA (IV,Injection) (NCT05966194)
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Brain metastases(Combination therapy) in USA (IV)
  • 09 Nov 2023 EpicentRx plans the phase II KEVLARx trial in Mucositis (NCT05966194)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top